Carlos Cordon-Cardo, MD, PhD Email Carlos Cordon-Cardo
- PROFESSOR AND SYSTEM CHAIR | Pathology
- PROFESSOR | Genetics and Genomic Sciences
- PROFESSOR | Oncological Sciences
Carlos Cordon-Cardo, MD, PhD is the Irene Heinz Given and John LaPorte Given Professor and Chairman for the Mount Sinai Health System Department of Pathology.
Dr. Cordon-Cardo obtained his MD from the Autonomous University of Barcelona, Spain, in 1980, and his PhD in Cell Biology and Genetics from Cornell University Medical College in 1985. Prior to joining Mount Sinai, Dr. Cordon-Cardo served as Vice-Chair of Pathology, Professor of Pathology, and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons. He also created the Division of Molecular Pathology at Memorial Sloan-Kettering Cancer Center and served as its first director.
Dr. Cordon-Cardo has outlined a broad vision that redefines the discipline of Pathology, placing it at the core of patient management and individualized medicine. An accomplished and internationally-recognized researcher, Dr. Cordon-Cardo is renowned for his studies on experimental pathology and molecular oncology. He developed and implemented an oncologic molecular pathology discipline and helped create the “systems pathology” platform. This approach uses systems biology to form mathematical models of the interaction and behavior of cancer cells with the goal of determining tumor pathogenesis and clinical outcome. Already his analyses of multi-drug resistance and alterations of tumor suppressor genes in human cancer, mainly those which deregulate cell cycle, have led to extraordinary breakthroughs in the way scientists understand and investigate the progression of certain solid-tumor cancers. His groundbreaking research has produced novel insights into tumor suppressor gene-oncogene interactions in human cancers, a proposed model for tumor progression of bladder cancer that defines two distinct pathways for early tumors, and evidence of the critical role of androgen receptor overexpression in the progression of prostate cancer and its resistance to hormonal therapy. Expression profiling using high through put microarrays has been a logical extension of the work carried out in his laboratory, providing novel insights into the molecular classification of human cancer. More recently, studies from his laboratory have linked adult stem cells and cancer, and have reported on the discovery of a subpopulation of human prostate tumor initiating cells with stem properties. This new cancer stem cell compartment has been identified in other solid tumors analyzed.
Dr. Cordon-Cardo has received numerous awards in acknowledgement of his significant contributions to the field of pathology, including the 1991 Boyer Young Investigator Award, the Gold Medal of the Swedish Society of Physicians, the Academico de Numero of the Academia Medico-Quirurgica Española, and the Gold Medal of Medical Sciences “Govierno de Galicia.” He is a member on the Roll of Honour of the International Union Against Cancer, and an honorary member of the Spanish-American Medical and Dental Society. Dr. Cordon-Cardo recently received an honorary doctorate from the Universidad de Barcelona, and was named a Member of Honor at the Reial Academia de Medicina de Catalunya. Dr. Cordon-Cardo is also a member of the World Health Organization Collaborating Centers for Urologic Tumors, and the State Legislative Committee of the American Association for Cancer Research. He served as the President for the Solid Tumor Chapter of the Association for Molecular Pathology, and Translational Chair for the Genitourinary Section of the Southwest Oncology Group. He also served as a member of the Review Committee for Cancer Centers and Research Programs of the NCI. More recently, Dr Cordon-Cardo earned the distinction of being listed on the European Journal of Clinical Investigation’s “List of 400 Most Highly Influential Biomedical Researchers Worldwide,” and a “Thought Leader” Award from Agilent Technologies.
In The News: Dr. Carlos Cordon-Cardo discusses new techniques in the fight against prostate cancer in The Daily News feature The Daily Check Up.
Cancer, Cancer Genetics, Cell Biology, Genomics, Molecular Biology, Pathology, Prostate, Proteomics, Stem Cells
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Data Science [GDS]
PhD, Cornell University Medical College
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer cell 2012 Sep; 22(3).
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer cell 2015 Feb; 27(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Cordon-Cardo during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Laboratorio Althia (Europath Biosciencies S.L.)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.